within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA03_Telavancin;

model Telavancin
  extends Pharmacolibrary.Drugs.ATC.J.J01XA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01XA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Telavancin is a lipoglycopeptide antibiotic used for the treatment of complicated skin and skin structure infections (cSSSI) and hospital-acquired and ventilator-associated bacterial pneumonia caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for intravenous use in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in adult healthy volunteers and infected patients from clinical studies. The data provided generally reflect administration of a single 10 mg/kg intravenous infusion over 60 minutes.</p><h4>References</h4><ol><li><p>Worboys, PD, et al., &amp; Barriere, SL (2015). Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. <i>European journal of clinical pharmacology</i> 71(6) 707–714. DOI:<a href=&quot;https://doi.org/10.1007/s00228-015-1847-6&quot;>10.1007/s00228-015-1847-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25939708/&quot;>https://pubmed.ncbi.nlm.nih.gov/25939708</a></p></li><li><p>Wong, SL, et al., &amp; Goldberg, MR (2008). Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. <i>The Journal of antimicrobial chemotherapy</i> 62(4) 780–783. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkn273&quot;>10.1093/jac/dkn273</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18586659/&quot;>https://pubmed.ncbi.nlm.nih.gov/18586659</a></p></li><li><p>Shaw, JP, et al., &amp; Kitt, MM (2010). Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. <i>Antimicrobial agents and chemotherapy</i> 54(8) 3365–3371. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01750-09&quot;>10.1128/AAC.01750-09</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20516282/&quot;>https://pubmed.ncbi.nlm.nih.gov/20516282</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Telavancin;
